Published in Food and Drug Law Weekly, February 2nd, 2007
The results appear to support Sernova's approach to treating diabetes in that Sertoli cells secrete, among other things, "substance P," the neuropeptide Toronto researchers injected into diabetic mice to reverse new onset diabetes. Sernova's approach to treating diabetes is to implant beneath the skin of diabetics, a small device containing insulin producing islets to reverse diabetes, and Sertoli...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.